Statistiche di base
| LEI | 529900OZKMF7JGZMYM81 |
| CIK | 1158780 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pluri Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 3, 2025 (June 30, 2025) PLURI INC. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 27, 2025 (May 21, 2025) PLURI INC. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. |
|
| May 21, 2025 |
PLURI INC. Matam Advanced Technology Park Building No. 5 Haifa, 3508409, Israel PLURI INC. Matam Advanced Technology Park Building No. 5 Haifa, 3508409, Israel May 21, 2025 Via EDGAR Doris Stacey Gama Tim Buchmiller Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Pluri Inc. (the “Company”) Preliminary Proxy Statement on Schedule 14A Filed March 14, 2025 File No. 001-31392 Dear Ms. Gama and Mr |
|
| May 13, 2025 |
Exhibit 10.3 AMENDMENT TO SECURITIES PURCHASE AGREEMENT This AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”) dated as of April 25, 2025, is made and entered into by and between Chutzpah Holdings Limited (the “Purchaser”) and Pluri Inc. (the “Company”). Each of the Company and the Purchaser shall be referred to collectively as the “Parties” and individually as a “Party.” WHEREAS, the |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as spec |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2025 (May 7, 2025) PLURI INC. |
|
| April 29, 2025 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 29, 2025 (April 25, 2025) PLURI INC. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2025 (April 28, 2025) PLURI INC. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. |
|
| April 25, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 25, 2025 |
Amendment to Securities Purchase Agreement Exhibit 10.1 AMENDMENT TO SECURITIES PURCHASE AGREEMENT This AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”) dated as of April 25, 2025, is made and entered into by and between Chutzpah Holdings Limited (the “Purchaser”) and Pluri Inc. (the “Company”). Each of the Company and the Purchaser shall be referred to collectively as the “Parties” and individually as a “Party.” WHEREAS, the |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2025 (April 25, 2025) PLURI INC. |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 17, 2025 (April 15, 2025) PLURI INC. |
|
| April 3, 2025 |
PLURI INC. Matam Advanced Technology Park Building No. 5 Haifa, 3508409, Israel PLURI INC. Matam Advanced Technology Park Building No. 5 Haifa, 3508409, Israel April 3, 2025 Via EDGAR Doris Stacey Gama Tim Buchmiller Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Pluri Inc. (the “Company,” “we,” “our” and similar terminology) Preliminary Proxy Statement on Schedule 14A Filed March 14, 2025 F |
|
| March 27, 2025 |
PLURI INC. Matam Advanced Technology Park Building No. 5 Haifa, 3508409, Israel PLURI INC. Matam Advanced Technology Park Building No. 5 Haifa, 3508409, Israel March 27, 2025 Via EDGAR Doris Stacey Gama Tim Buchmiller Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Pluri Inc. (the “Company,” “we,” “our” and similar terminology) Preliminary Proxy Statement on Schedule 14A Filed March 14, 2025 |
|
| March 19, 2025 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 19, 2025 (March 13, 2025) PLURI INC. |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. |
|
| March 13, 2025 |
Form of Assignment and Assumption Agreement Exhibit 10.2 ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (“Agreement”) is made and entered into effective on , 2025 (“Effective Date”) by and between [name of assignor] (“Assignor”) and Pluri Biotech Ltd. (“Assignee”). The Assignee and the Assignor are referred to herein individually as a “Party” and collectively as the “Parties.” RECITALS WHEREAS The Assignor, Ass |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2025 (March 12, 2025) PLURI INC. |
|
| March 13, 2025 |
Exhibit 99.1 LEAK OUT AGREEMENT This Leak Out Agreement (the “Leak-Out Agreement” or the “Agreement”) is made and entered into as of , 2025, between Pluri, Inc., a Nevada corporation whose address is (the “Company”), and [*], whose address is [*] (the “Holder”). Each of the Company and the Holder referred to as a “party” to this Agreement, and collectively, the “parties”. Reference is hereby made |
|
| March 13, 2025 |
Form of Share Purchase Agreement Exhibit 10.1 Share Purchase Agreement This Share Purchase Agreement (the “Agreement”) is made and entered into effect as of the 12st day of March, 2025 (the “Effective Date”), by and between (i) Pluri Inc., a company organized and existing under the laws of the State of Nevada (the “Parent”) and Pluri Biotech Ltd a company organized under the laws of the State of Israel, and a wholly owned subsidi |
|
| February 11, 2025 |
Form of RSU and options waiver letter agreement. Exhibit 10.4 Form of RSU and Options Waiver Letter Agreement January [], 2025 [Mr./ Mrs. ] [Address] Re: RSU Vesting Acceleration Waiver On [] [and on []], Pluri Inc. (the “Company”) issued you a restricted stock unit representing [] of the Company’s common shares (the “RSUs”). [On [] [and on []], Pluri Inc. (the “Company”) granted you an option representing [] of the Company’s common shares (the |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as s |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2025 (February 3, 2025) PLURI INC. |
|
| February 6, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 6, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 3, 2025, between Pluri Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section |
|
| January 29, 2025 |
Exhibit 10.2 BINDING TERM SHEET FOR For Proposed Acquisition of Securities of kokomodo ltd. January 23, 2025 1. Selling Party Chutzpah Holdings Ltd. and Plantae Ltd. (jointly and severally: the “Selling Party” or “Seller”). 2. Purchaser Pluri, Inc. a Nevada public corporation traded on Nasdaq, (“Purchaser”, and together with Selling Party: the “Parties”). 3. Transaction Subject to the herein terms |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2025 (January 23, 2025) PLURI INC. |
|
| January 29, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 29, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 23, 2025, between Pluri Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section |
|
| January 29, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 21, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 21, 2025 (January 15, 2025) PLURI INC. |
|
| November 27, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 27, 2024 (November 25, 2024) PLURI INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2024 (September 26, 2024) PLURI INC. |
|
| September 18, 2024 |
Exhibit 97.1 PLURI INC. (the “Company”) CLAWBACK POLICY Effective as of November 13, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Compensa |
|
| September 18, 2024 |
Exhibit 4.1 DESCRIPTION OF SECURITIES Under the Amended and Restated Articles of Incorporation, as amended (the “Articles”), of Pluri Inc. (the “Company”), the Company is authorized to issue up to Thirty Seven Million Five Hundred Thousand (37,500,000) shares of common stock, par value $0.00001 per share (the “Common Stock”), and one million (1,000,000) shares of preferred stock, par value $0.0000 |
|
| September 18, 2024 |
Exhibit 10.34 Amended and Restated Employment Agreement Duly made and executed on the date set forth in Appendix 1 By and Between Pluri biotech Ltd. Company number 513371666 (hereinafter the “Company”) and Liat Zalts I.D. 41706953 (hereinafter the “Employee”) (other details as set forth in Appendix 1) WHEREAS, the Employee has been employed by the Company since December 11, 2022 as Director of Fin |
|
| September 18, 2024 |
List of Subsidiaries of the Company. Exhibit 21.1 List of Subsidiaries of Pluri Inc. Pluri Biotech Ltd., an Israeli company. Pluristem GmbH, incorporated under the laws of Germany. Ever After Foods Ltd. (69% are held by Pluri Biotech Ltd.) Coffeesai Ltd. |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURI INC. (Ex |
|
| July 23, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 23, 2024 (July 19, 2024) PLURI INC. |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2024 (July 8, 2024) PLURI INC. |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 2, 2024 (June 30, 2024) PLURI INC. |
|
| June 26, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 26, 2024 (June 25, 2024) PLURI INC. |
|
| June 18, 2024 |
Share Purchase Agreement, dated June 12, 2024, by and among Ever After and the Investors. Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO PLURI INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is entered into on June 12, 2024, by and among (i) Eve |
|
| June 18, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 18, 2024 (June 12, 2024) PLURI INC. |
|
| June 18, 2024 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO PLURI INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT THIS AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT is made and entered int |
|
| May 31, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 28, 2024 PLURI INC. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PLURI INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Newly Registered Securities Fees |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PLURI INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Newly Registered Securities Fees |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as spec |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Exhibit 3.3 PLURI INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of March 27, 2024 FIRST The name of this corporation is PLURI INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name and address of its resident agent is CSC Services of Nevada, Inc., at the above address. THIRD The purpose or purposes for wh |
|
| May 9, 2024 |
Composite Copy (marked) of the Company’s Articles of Incorporation as amended on March 27, 2024. Exhibit 3.4 PLURI INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of May 1, 2023 March 27, 2024 FIRST The name of this corporation is PLURI INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name and address of its resident agent is CSC Services of Nevada, Inc., at the above address. THIRD The purpose or pur |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 17, 2024 (April 15, 2024) PLURI INC. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 27, 2024 PLURI INC. |
|
| April 1, 2024 |
Exhibit 3.2 |
|
| April 1, 2024 |
Exhibit 3.1 FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701 - 4201 (775) 684 - 5708 Website: www.nvsos.gov Certificate of Change Pursuant to NRS 78.209 TYPE OR PRINT - USE DARK INK ONLY - DO NOT HIGHLIGHT This form must be accompanied by appropriate fees. If necessary, additional pages may be attached to this form. Page 1 of 1 Revised: 8/1/2023 INSTRUCTION |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 13, 2024 (February 13, 2024) PLURI INC. |
|
| February 13, 2024 |
Up to $10,000,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-273347 PROSPECTUS SUPPLEMENT (to prospectus dated September 21, 2023) Up to $10,000,000 Common Shares We have entered into a sales agreement with A.G.P./Alliance Global Partners, or A.G.P. or the Sales Agent, dated February 13, 2024, relating to the sale of our common shares offered by this prospectus supplement. In accordance with the terms of |
|
| February 13, 2024 |
Sales Agreement, dated February 13, 2024, by and between the Company and A.G.P. Exhibit 1.1 Pluri Inc. COMMON SHARES SALES AGREEMENT February 13, 2024 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Pluri Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time |
|
| February 13, 2024 |
Agreement of Joint Filing, dated as of February 13, 2024, by and among the Reporting Persons. EX-99.1 2 ea193604ex99-1pluriinc.htm AGREEMENT OF JOINT FILING, DATED AS OF FEBRUARY [ ], 2024, BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13G/A with respect to the shares of Pluri Inc. dated as of February 13, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shal |
|
| February 13, 2024 |
IL:PLUR / Pluri Inc. / Shayna LP - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea193604-13ga2shaynapluri.htm AMENDMENT NO. 2 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 PLURI INC. (Name of Issuer) Common Shares, par value $0.00001 per share (Title of Class of Securities) 72942G 104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this St |
|
| February 12, 2024 |
Form of Restricted Stock Unit Agreement (employees) under the 2016 Equity Compensation Plan Exhibit 10.1 Pluri Inc. RESTRICTED STOCK UNITS AGREEMENT Made as of BETWEEN: Pluri Inc. A company incorporated in Nevada, USA (hereinafter the “Company”) AND: Name : I.D. No.: Address: (hereinafter the “Participant”) WHEREAS on March 29, 2016, the Company duly adopted and the Compensation Committee approved the 2016 Equity Compensation Plan and on May 31, 2016, the Company’s stockholders approved |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as s |
|
| February 12, 2024 |
Exhibit 10.6 AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) dated as of December 25, 2023, by and between Pluri-Biotech Ltd. (the “Company”) and Mr. Yaacov (Yaky) Yanay (the “Executive”). Each of the Company and the Executive shall be referred to collectively as the “Parties” and individually as a “Party |
|
| February 12, 2024 |
Exhibit 10.5 AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) dated as of December 1, 2023, by and between Pluri-Biotech Ltd. (the “Company”) and Ms. Chen Franco -Yehuda (the “Executive”). Each of the Company and the Executive shall be referred to collectively as the “Parties” and individually as a “Party. |
|
| February 12, 2024 |
Amendment No. 1 to Consulting Agreement with Mr. Zalman (Zami) Aberman Exhibit 10.7 Amendment #1 to the Consulting Agreement This Amendment #1 to the Consulting Agreement (“Amendment #1”) effective as of the 1st of December, 2023 (the “Effective Date”), is entered into between Pluri Biotech Ltd. a with its principal place of business at MATAM Park, Building 5, Haifa 31905 Israel (“Company”) and Mr. Zalman (Zami) Aberman, Israeli ID# 26014043 from Tel Mond, Israel (“C |
|
| February 12, 2024 |
Exhibit 10.3 Pluri Inc. RESTRICTED STOCK UNITS AGREEMENT Made as of BETWEEN: Pluri Inc. A company incorporated in Nevada, USA (hereinafter the “Company”) AND: Name: I.D. No.: Address: (hereinafter the “Participant”) WHEREAS on March 29, 2016, the Company duly adopted and the Compensation Committee approved the 2016 Equity Compensation Plan and on May 31, 2016, the Company’s stockholders approved t |
|
| February 12, 2024 |
Exhibit 10.2 Pluri Inc. RESTRICTED STOCK UNITS AGREEMENT Made as of BETWEEN: Pluri Inc. A company incorporated in Nevada, USA (hereinafter the “Company”) AND: Name: I.D. No.: Address: (hereinafter the “Participant”) WHEREAS on March 29, 2016, the Company duly adopted and the Compensation Committee approved the 2016 Equity Compensation Plan and on May 31, 2016, the Company’s stockholders approved t |
|
| February 12, 2024 |
Summary of Directors’ Ongoing Compensation Exhibit 10.4 Summary of Directors Ongoing Compensation Effective as January 23, 2024, our non-executive officer directors receive cash compensation as follows: ● Annual compensation of $35,000; ● The Chairman of our Audit Committee shall receive an additional annual fee of $10,000 and in the event of an annual equity grant issued to directors, or an Annual Director Grant, an additional 10% of equi |
|
| February 1, 2024 |
IL:PLUR / Pluri Inc. / Slager David Mark - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea192665-13ga2slagerpluri.htm AMENDMENT NO. 2 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* PLURI INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72942G 104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this St |
|
| February 1, 2024 |
Agreement of Joint Filing. (Filed herewith) EX-99.1 2 ea192665ex99-1pluriinc.htm AGREEMENT OF JOINT FILING Exhibit 99.1 AGREEMENT OF JOINT FILING The undersigned hereby agree that the Schedule 13G with respect to the shares of common stock, $0.00001 par value per share, of Pluristem Therapeutics Inc., dated as of February 1, 2024, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursua |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 24, 2024 (January 23, 2024) PLURI INC. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 8, 2024 (January 8, 2024) PLURI INC. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as |
|
| October 19, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 19, 2023 (October 17, 2023) PLURI INC. |
|
| September 19, 2023 |
Pluri Inc. MATAM Advanced Technology Park Building No. 5 Haifa, Israel 3508409 Pluri Inc. MATAM Advanced Technology Park Building No. 5 Haifa, Israel 3508409 September 19, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Pluri Inc. Registration Statement on Form S-3 Filed July 20, 2023 File No. 333-273347 Ladies and Gentlemen: Pluri Inc. (the “Company”) hereby re |
|
| September 15, 2023 |
Agreement of Joint Filing, dated as of September 15, 2023, by and among the Reporting Persons. EX-99.1 2 ea185292ex99-1pluri.htm AGREEMENT OF JOINT FILING, DATED AS OF SEPTEMBER 15, 2023, BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13G/A with respect to the shares of Pluri Inc. dated as of September 15, 2023, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall |
|
| September 15, 2023 |
IL:PLUR / Pluri Inc / Shayna LP - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea185292-13ga1shaynapluri.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 PLURI INC. (Name of Issuer) Common Shares, par value $0.00001 per share (Title of Class of Securities) 72942G 104 (CUSIP Number) December 22, 2022 (Date of Event Which Requires Filing of this St |
|
| September 12, 2023 |
As filed with the Securities and Exchange Commission on September 12, 2023 As filed with the Securities and Exchange Commission on September 12, 2023 Registration No. |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURI INC. (Ex |
|
| July 20, 2023 |
As filed with the Securities and Exchange Commission on July 20, 2023 As filed with the Securities and Exchange Commission on July 20, 2023 Registration No. |
|
| July 20, 2023 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) PLURI INC. .(Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward For |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 13, 2023 (July 11, 2023) PLURI INC. |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 11, 2023 (July 11, 2023) PLURI INC. |
|
| June 6, 2023 |
Pluri Inc. MATAM Advanced Technology Park Building No. 5 Haifa, Israel 3508409 Pluri Inc. MATAM Advanced Technology Park Building No. 5 Haifa, Israel 3508409 June 6, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Tim Buchmiller Re: Pluri Inc. Registration Statement on Form S-3 Filed June 1, 2023 File No. 333-272330 Ladies and Gentlemen: Pluri Inc. (the “Company”) hereby requests acc |
|
| June 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Pluri Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit (1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Shares, $0.0001 par value per share (2 |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 As filed with the Securities and Exchange Commission on June 1, 2023 Registration No. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as spec |
|
| May 9, 2023 |
Exhibit 3.1 PLURI INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of May 1, 2023 FIRST The name of this corporation is PLURI INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name and address of its resident agent is CSC Services of Nevada, Inc., at the above address. THIRD The purpose or purposes for which |
|
| May 9, 2023 |
Composite Copy (marked) of the Company’s Articles of Incorporation as amended on May 1, 2023. Exhibit 3.2 PLURISTEM THERAPEUTICS PLURI INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of July 2, 2020 May 1, 2023 FIRST The name of this corporation is PLURISTEM THERAPEUTICS PLURI INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name and address of its resident agent is CSC Services of Nevada, Inc., at |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2023 PLURI INC. |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 19, 2023 (April 25, 2023) PLURI INC. |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. |
|
| February 16, 2023 |
US72942G1040 / PLURI INC / Shayna LP - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PLURI INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72942G 104 (CUSIP Number) December 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 14, 2023 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| February 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PLURI INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Newly Registered Securities Fees |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as s |
|
| February 13, 2023 |
Exhibit 10.2 Consulting Agreement This Consulting Agreement (the “Agreement”) is entered into as of January 1st 2023 (the “Effective Date”) by and between Pluri Biotech Ltd., with its principal place of business at MATAM Park, Building 5, Haifa 31905 Israel (“Company”), and Mr. Zalman (Zami) Aberman, Israeli ID# 26014043 from Tel Mond, Israel (“Consultant”). (Each may be referred to as a “Party” a |
|
| February 13, 2023 |
As filed with the Securities and Exchange Commission on February 13, 2023 As filed with the Securities and Exchange Commission on February 13, 2023 Registration No. |
|
| February 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PLURI INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Newly Registered Securities Fees |
|
| February 13, 2023 |
As filed with the Securities and Exchange Commission on February 13, 2023 S-8 1 ea173133-s8pluriinc.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on February 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLURI INC. (Exact name of registrant as specified in its charter) Nevada 98-0351734 (State or other jurisdiction o |
|
| February 6, 2023 |
US72942G1040 / PLURI INC / Slager David Mark - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea172803-13ga1slagerpluri.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PLURI INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72942G 104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this St |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2023 (February 6, 2023) PLURI INC. |
|
| February 6, 2023 |
EX-99.1 2 ea172803ex99-1pluri.htm AGREEMENT OF JOINT FILING Exhibit 99.1 AGREEMENT OF JOINT FILING The undersigned hereby agree that the Schedule 13G with respect to the shares of common stock, $0.00001 par value per share, of Pluristem Therapeutics Inc., dated as of February 6, 2023, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 24, 2023 (January 23, 2023) PLURI INC. |
|
| January 4, 2023 |
US72942G1040 / PLURI INC / YANAY YAKY - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) PLURI INC. (Name of Issuer) Common Shares, par value $0.00001 per share (Title of Class of Securities) 72942G 104 (CUSIP Number) Yaky Yanay Chen |
|
| January 4, 2023 |
EX-99.2 2 ea171242ex99-2pluri.htm JOINT FILING AGREEMENT, DATED AS OF JANUARY 4, 2023, BY AND BETWEEN YAKY YANAY AND CHEN FRANCO-YEHUDA Exhibit 2 JOINT FILING AGREEMENT Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attac |
|
| December 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 28, 2022 (December 22, 2022) PLURI INC. |
|
| December 28, 2022 |
Exhibit 99.1 Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept ? Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional biologics technology partnership; ? Joint venture with Tnuva reaches proof of concept an |
|
| December 19, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 19, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December [], 2022, between Pluri Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth i |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2022 (December 13, 2022) PLURI INC. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURI INC. (Exact name of registrant as |
|
| October 13, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 13, 2022 (October 12, 2022) PLURI INC. |
|
| September 29, 2022 |
Exhibit 99.1 Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates ? New company strategy will reduce cash burn by approximately 30%, with $56M in cash on consolidated balance sheet ? Leading European manufacturer of active pharmaceutical ingredients (APIs) to use Pluri?s 3D cell expansion technology, which aims to |
|
| September 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 29, 2022 (September 29, 2022) PLURI INC. |
|
| September 21, 2022 |
List of Subsidiaries of the Company. Exhibit 21.1 List of Subsidiaries of Pluri Inc. Pluri Biotech Ltd., previously named Pluristem Ltd., an Israeli company. Pluristem GmbH, incorporated under the laws of Germany. Plurinuva Ltd., an Israeli company. |
|
| September 21, 2022 |
Pluri Inc. Up to $11,800,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-239890 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated July 23, 2020 To Prospectus dated July 23, 2020) Pluri Inc. Up to $11,800,000 Common Shares This prospectus supplement amends and supplements the information in the prospectus, dated July 23, 2020, filed with the Securities and Exchange Commission as a part of our registration stateme |
|
| September 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURI INC. (Ex |
|
| July 25, 2022 |
Exhibit 3.1 |
|
| July 25, 2022 |
Pluri CEO Issues Shareholder Update Exhibit 99.1 Pluri CEO Issues Shareholder Update HAIFA, Israel, July 25, 2022 ? Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (?Pluri? or the ?Company?) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Pluri: One simple, short word of Greek origin that encapsulates the s |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 25, 2022 (July 22, 2022) PLURI INC. |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 13, 2022 (July 13, 2022) PLURISTEM THERAPEUTICS INC. |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2022 (June 21, 2022) PLURISTEM THERAPEUTICS INC. |
|
| May 9, 2022 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO PLURISTEM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this ?Agreement?) is entered into on January 5, 2022, b |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of r |
|
| May 9, 2022 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO PLURISTEM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. TECHNOLOGY LICENSE AGREEMENT THIS TECHNOLOGY LICENSE AGREEMENT is made and entered into this 5th day of January |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 24, 2022 (March 23, 2022) PLURISTEM THERAPEUTICS INC. |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 8, 2022 (March 8, 2022) PLURISTEM THERAPEUTICS INC. |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2022 (February 24, 2022) PLURISTEM THERAPEUTICS INC. |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name o |
|
| February 7, 2022 |
Exhibit 10.2 English Summary of Supplement to Lease Agreement Dated December 31, 2021 A supplement dated December 31, 2021 (the ?Supplement?) made to the existing lease agreement dated January 22, 2003 (the ?Lease Agreement?) 1. Parties: Pluristem Ltd. (?Pluristem?) and MTM ? Scientific Industries Center Haifa Ltd. (?MTM?). 2. Signing Date: December 31, 2021 3. The Premises: Certain areas in Build |
|
| January 26, 2022 |
PSTI / Pluristem Therapeutics Inc. / Slager David Mark - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PLURISTEM THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72940R300 (CUSIP Number) January 24, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 26, 2022 |
Exhibit 99.1 AGREEMENT OF JOINT FILING The undersigned hereby agree that the Schedule 13G with respect to the shares of common stock, $0.00001 par value per share, of Pluristem Therapeutics Inc., dated as of January 26, 2022, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) un |
|
| January 10, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2022 (January 5, 2022) PLURISTEM THERAPEUTICS INC. |
|
| January 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2022 (January 1, 2022) PLURISTEM THERAPEUTICS INC. |
|
| January 3, 2022 |
Exhibit 10.1 Consulting Agreement This Consulting Agreement (the ?Agreement?) is entered into as of January 1st 2022 (the ?Effective Date?) by and between Pluristem Ltd., with its principal place of business at MATAM Park, Building 5, Haifa 31905 Israel (?Company?), and Mr. Zalman (Zami) Aberman, Israeli ID# 26014043 from Tel Mond, Israel (?Consultant?). (Each may be referred to as a ?Party? and c |
|
| December 27, 2021 |
Exhibit 99.1 Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19 HAIFA, Israel, Dec 27, 2021 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the ?Company?), a leading biotechnology company, today announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular inj |
|
| December 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 27, 2021 (December 27, 2021) PLURISTEM THERAPEUTICS INC. |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 16, 2021 (November 15, 2021) PLURISTEM THERAPEUTICS INC. |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name |
|
| September 13, 2021 |
Exhibit 10.19 Pluristem Therapeutics Inc. RESTRICTED STOCK UNITS AGREEMENT Made as of BETWEEN: Pluristem Therapeutics Inc. A company incorporated in Nevada, USA (hereinafter the ?Company?) AND: Name: I.D. No.: Address: (hereinafter the ?Participant?) WHEREAS on March 28, 2019, the Company duly adopted and the Compensation Committee approved the 2019 Equity Compensation Plan and on June 13, 2019, t |
|
| September 13, 2021 |
Exhibit 10.20 Pluristem Therapeutics Inc. RESTRICTED STOCK UNITS AGREEMENT Made as of BETWEEN: Pluristem Therapeutics Inc. A company incorporated in Nevada, USA (hereinafter the ?Company?) AND: Name : I.D. No.: Address: (hereinafter the ?Participant?) WHEREAS on March 28, 2019, the Company, and the Compensation Committee, duly adopted and approved the 2019 Equity Compensation Plan and on June 13, |
|
| September 13, 2021 |
Exhibit 10.28 AGREEMENT This CLARIFICATION TO AMENDED AND RESTATED CONSULTING AGREEMENT (this ?Agreement?) dated as of September 13, 2021, by and between Pluristem Ltd. (the ?Company?) and Rose High Tech Ltd. of Tel Mond, Israel (the ?Consultant?). Each of the Company and the Consultant shall be referred to collectively as the ?Parties? and individually as a ?Party.? W I T N E S S E T H WHEREAS, t |
|
| September 13, 2021 |
Exhibit 10.29 AGREEMENT This CLARIFICATION TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) dated as of September 13, 2021, by and between Pluristem Ltd. (the ?Company?) and Mr. Yaacov (Yaky) Yanay (the ?Executive?). Each of the Company and the Executive shall be referred to collectively as the ?Parties? and individually as a ?Party.? W I T N E S S E T H: WHEREAS, the Company and th |
|
| September 13, 2021 |
Exhibit 10.18 Pluristem Therapeutics Inc. RESTRICTED STOCK UNITS AGREEMENT Made as of BETWEEN: Pluristem Therapeutics Inc. A company incorporated in Nevada, USA (hereinafter the ?Company?) AND: Name : I.D. No.: Address: (hereinafter the ?Participant?) WHEREAS, on March 28, 2019, the Company duly adopted and the Compensation Committee approved the 2019 Equity Compensation Plan and on June 13, 2019, |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THER |
|
| September 13, 2021 |
Exhibit 10.30 AGREEMENT This CLARIFICATION TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) dated as of September 13, 2021, by and between Pluristem Ltd. (the ?Company?) and Ms. Chen Franco-Yehuda (the ?Executive?). Each of the Company and the Executive shall be referred to collectively as the ?Parties? and individually as a ?Party.? W I T N E S S E T H: WHEREAS, the Company and the |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 19, 2021 (July 15, 2021) PLURISTEM THERAPEUTICS INC. |
|
| July 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2021 (July 8, 2021) PLURISTEM THERAPEUTICS INC. |
|
| June 2, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 2, 2021 (June 2, 2021) PLURISTEM THERAPEUTICS INC. |
|
| June 1, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PLURISTEM THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72940R300 (CUSIP Number) May 28, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 25, 2021 (May 25, 2021) PLURISTEM THERAPEUTICS INC. |
|
| May 6, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of r |
|
| May 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 3, 2021 (May 3, 2021) PLURISTEM THERAPEUTICS INC. |
|
| May 3, 2021 |
Investor presentation (furnished herewith) Exhibit 99.1 |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 29, 2021 (April 29, 2021) PLURISTEM THERAPEUTICS INC. |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. |
|
| March 25, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2021 (March 25, 2021) PLURISTEM THERAPEUTICS INC. |
|
| March 25, 2021 |
Exhibit 16.1 March 25, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated March 25, 2021 of Pluristem Therapeutics Inc. and are in agreement with the statements contained in the second, third and fourth of Item 4.01. We have no basis to agree or disagree with other statements of the registrant contained the |
|
| February 8, 2021 |
EX-10.1 2 f10q1220ex10-1pluristem.htm FORM OF DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT Exhibit 10.1 PLURISTEM THERAPEUTICS INC. This Agreement is made as of the day of , by and between Pluristem Therapeutics Inc., a Nevada corporation (the “Corporation”), and (“Indemnitee”), a director and/or officer of the Corporation. WHEREAS, it is essential to the Corporation to retain and attract as dir |
|
| February 8, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name o |
|
| February 5, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PLURISTEM THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72940R300 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 3, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 2, 2021, between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| February 3, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 3, 2021 (February 2, 2021) PLURISTEM THERAPEUTICS INC. |
|
| February 3, 2021 |
4,761,905 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-239890 PROSPECTUS SUPPLEMENT (to the Prospectus dated July 23, 2020) 4,761,905 Shares of Common Stock We are offering 4,761,905 shares of our common stock, par value $0.00001 per share, at an offering price of $6.30 per share. Our common stock is listed on The Nasdaq Global Market, or Nasdaq, under the symbol “PSTI” and on the Tel Aviv Stock Ex |
|
| February 3, 2021 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT February 2, 2021 Pluristem Therapeutics Inc. MATAM Advanced Technology Park Building No. 5 Haifa L3 31905 Israel Attention: Chen Franco-Yehuda Chief Financial Officer Dear Mr. Franco-Yehuda: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (“A.G.P.”)(A.G.P. is also referred to as, the “Placem |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 6, 2021 (January 5, 2021) PLURISTEM THERAPEUTICS INC. |
|
| December 9, 2020 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 9, 2020 (December 9, 2020) PLURISTEM THERAPEUTICS INC. |
|
| December 9, 2020 |
December 9 , 2020 PLURISTEM CONFERENCE CALL Inspired by Life Exhibit 99.1 December 9 , 2020 PLURISTEM CONFERENCE CALL Inspired by Life 2 This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws . For example, we are using forward - looking statements when we discuss that we expect topline clinical results during the calendar year 2021 with |
|
| November 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 18, 2020 (November 18, 2020) PLURISTEM THERAPEUTICS INC. |
|
| November 5, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name |
|
| November 5, 2020 |
Exhibit 10.2 Contract number (FI No): 92335 Contract number (FI No): 91870 Serapis No: 2019-0880 Innovative Cell Therapies (EGFF) Guarantee Agreement between the European Investment Bank and Pluristem Ltd. and Pluristem GmbH 30 September, 2020 Article 1 INTERPRETATION AND DEFINITIONS 2 1.01 Interpretation 2 1.02 Definitions 3 Article 2 FINANCE DOCUMENTS 5 Article 3 GUARANTEE 5 3.01 Guarantee (Gara |
|
| November 5, 2020 |
Exhibit 10.1 Contract number (FI No): 92335 Contract number (FI No): 91870 Serapis No: 2019-0880 Innovative Cell Therapies (EGFF) Guarantee Agreement between the European Investment Bank and Pluristem Therapeutics Inc. and Pluristem GmbH 30 September, 2020 Article 1 INTERPRETATION AND DEFINITIONS 2 1.01 Interpretation 2 1.02 Definitions 3 Article 2 FINANCE DOCUMENTS 5 Article 3 GUARANTEE 5 3.01 Gu |
|
| October 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 7, 2020 (October 7, 2020) PLURISTEM THERAPEUTICS INC. |
|
| October 5, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* PLURISTEM THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72940R300 (CUSIP Number) September 29, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| September 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 15, 2020 (September 15, 2020) PLURISTEM THERAPEUTICS INC. |
|
| September 10, 2020 |
Exhibit 10.17 Amended and Restated Consulting Agreement This Consulting Agreement (this “Agreement”) is entered into as of September 10, 2020 (the “Effective Date”) by and between Pluristem Ltd., with its principal place of business at MATAM Park, Building 5, Haifa 31905 Israel (“Company”), and Rose High Tech Ltd. of Tel Mond, Israel (“Consulting Company”). (Each may be referred to as a “Party” an |
|
| September 10, 2020 |
Exhibit 10.19 Amended and Restated Employment Agreement Duly made and executed on the date set forth in Appendix 1 By and Between Pluristem Ltd. Company number 513371666 (hereinafter the “Company”) and Chen Franco Yehuda I.D. 038749859 (hereinafter the “Employee”) (other details as set forth in Appendix 1) WHEREAS, the Employee has been employed by the Company since May 1, 2013 and the Employee an |
|
| September 10, 2020 |
Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF PLURISTEM THERAPEUTICS, INC. A Nevada Corporation ARTICLE I STOCKHOLDERS SECTION 1 Annual Meeting. Annual meetings of the Stockholders, shall be held annually on the day and at the time as may be set by the Board of Directors from time to time, at which annual meeting the Stockholders shall elect by vote a Board of Directors and transact such other busine |
|
| September 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THER |
|
| September 10, 2020 |
List of Subsidiaries of the Company. Exhibit 21.1 List of Subsidiaries of the Pluristem Therapeutics Inc. Pluristem, Ltd., an Israeli company. Pluristem GmbH, incorporated under the laws of Germany. |
|
| September 10, 2020 |
Exhibit 10.8 Summary of Directors Ongoing Compensation Effective as September 10, 2020, our non-executive officer directors receive cash compensation as follows: ● Annual compensation of $35,000; ● The Chairman of our Audit Committee shall receive an additional annual fee of $10,000 and in the event of an annual equity grant issued to directors, or an Annual Director Grant, an additional 10% of eq |
|
| September 10, 2020 |
Exhibit 10.20 Execution Version Contract number (FI No): 92335 Contract number (FI No): 91870 Serapis No: 2019-0880 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO PLURISTEM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS WITH ASTERISKS THROUGHOUT THIS EXHIBIT. Innovati |
|
| September 10, 2020 |
Amended and Restated By-laws as amended on September 10, 2020 (marked). Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF PLURISTEM THERAPEUTICS, INC. A Nevada Corporation ARTICLE I STOCKHOLDERS SECTION 1 Annual Meeting. Annual meetings of the Stockholders, shall be held annually on the day and at the time as may be set by the Board of Directors from time to time, at which annual meeting the Stockholders shall elect by vote a Board of Directors and transact such other busine |
|
| September 10, 2020 |
Exhibit 4.3 DESCRIPTION OF SECURITIES Under the Amended and Restated Articles of Incorporation (the “Articles”) of Pluristem Therapeutics Inc. (the “Company”), the Company is authorized to issue up to sixty million (60,000,000) shares of common stock, par value $0.00001 per share (the “Common Stock”) and one million (1,000,000) shares of preferred stock, par value $0.00001 per share (the “Preferre |
|
| September 10, 2020 |
Exhibit 10.18 Amended and Restated Employment Agreement Duly made and executed on the date set forth in Appendix 1 By and Between Pluristem Ltd. Company number 513371666 (hereinafter the “Company”) and Yaacov (Yaky) Yanay I.D. 28621605 (hereinafter the “Employee”) (other details as set forth in Appendix 1) WHEREAS, the Employee has been employed by the Company since October 15, 2006 and the Employ |
|
| September 9, 2020 |
As filed with the Securities and Exchange Commission on September 9, 2020 Registration No. |
|
| September 9, 2020 |
As filed with the Securities and Exchange Commission on September 9, 2020 Registration No. |
|
| August 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 27, 2020 (August 27, 2020) PLURISTEM THERAPEUTICS INC. |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2020 (August 10, 2020) PLURISTEM THERAPEUTICS INC. |
|
| July 22, 2020 |
CORRESP 1 filename1.htm Pluristem Therapeutics Inc. MATAM Advanced Technology Park, Building No. 5 Haifa L3 31905 Israel July 22, 2020 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Laura Crotty Re: Pluristem Therapeutics Inc. Registration Statement on Form S-3 Filed July 16, 2020 File No. 333-239890 Ladies an |
|
| July 21, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 21, 2020 (July 21, 2020) PLURISTEM THERAPEUTICS INC. |
|
| July 21, 2020 |
Pluristem CEO Issues Shareholder Update on Clinical Programs Exhibit 99.1 Pluristem CEO Issues Shareholder Update on Clinical Programs HAIFA, Israel, July 21, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay. Dear Fellow Shareholders, During this challen |
|
| July 16, 2020 |
Exhibit 4.1 PLURISTEM THERAPEUTICS INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of July 2, 2020 FIRST The name of this corporation is PLURISTEM THERAPEUTICS INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name and address of its resident agent is CSC Services of Nevada, Inc., at the above address. THIR |
|
| July 16, 2020 |
As filed with the Securities and Exchange Commission on July 16, 2020 Registration No. |
|
| July 16, 2020 |
Exhibit 4.2 PLURISTEM THERAPEUTICS INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of July 25, 2019 July 2, 2020 FIRST The name of this corporation is PLURISTEM THERAPEUTICS INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name and address of its resident agent is CSC Services of Nevada, Inc., at the above |
|
| July 16, 2020 |
Exhibit 1.2 Execution Version OPEN MARKET SALE AGREEMENTSM July 16, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the |
|
| July 16, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 16, 2020 (July 16, 2020) PLURISTEM THERAPEUTICS INC. |
|
| July 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2020 (June 29, 2020) PLURISTEM THERAPEUTICS INC. |
|
| June 30, 2020 |
SC 13G/A 1 ea0123544-13ga1cloverplur.htm AMENDMENT NO. 1 TO SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PLURISTEM THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72940R300 (CUSIP Number) May 27, 2020 (Date of Event Which Requires Filing of th |
|
| June 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 11, 2020 (June 11, 2020) PLURISTEM THERAPEUTICS INC. |
|
| May 20, 2020 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 ea122215-defa14apluristem.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Prelim |
|
| May 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. |
|
| May 18, 2020 |
Pluristem Therapeutics Inc. Matam Advanced Technology Park Building No. 5 Haifa, Israel, 31905 May 18, 2020 Division of Corporation Finance, Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-6010 Attention: Chris Edwards Re: Pluristem Therapeutics Inc. (the “Company”) Preliminary Proxy Statement on Schedule 14A (the “Preliminary Proxy” |
|
| May 18, 2020 |
PRER14A 1 ea122017-prer14apluristem.htm AMENDED PRELIMINARY 14A. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary P |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2020 (May 14, 2020) PLURISTEM THERAPEUTICS INC. |
|
| May 11, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of r |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2020 (May 8, 2020) PLURISTEM THERAPEUTICS INC. |
|
| May 6, 2020 |
1,587,302 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-218916 PROSPECTUS SUPPLEMENT (to the Prospectus dated June 30, 2017) 1,587,302 Shares of Common Stock We are offering 1,587,302 shares of our common stock, par value $0.00001 per share, at an offering price of $9.45 per share. Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “PSTI” and on the Tel Aviv Stock E |
|
| May 5, 2020 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 5, 2020, between Pluristem Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 5, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 5, 2020 (May 5, 2020) PLURISTEM THERAPEUTICS INC. |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 30, 2020 (April 30, 2020) PLURISTEM THERAPEUTICS INC. |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 30, 2020 |
EX-99.1 2 ea121226ex99-1pluristemther.htm INVESTOR & ANALYST CALL FINANCING AGREEMENT BETWEEN PLURISTEM AND EIB, DATED APRIL 30, 2020 Exhibit 99.1 1 NASDAQ / TASE :NNDM www.nano-di.com | © 2020 Nano Dimension. All rights reserved. Nano Dimension is a Developer & Provider of Intelligent Machines and ConsumableConductive&DielectricMaterials(Inks)fortheFabricationof AdditivelyManufacturedElectronics( |
|
| April 29, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PLURISTEM THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 72940R300 (CUSIP Number) April 3, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| April 29, 2020 |
Exhibit 99.1 AGREEMENT OF JOINT FILING The undersigned hereby agree that the Schedule 13G with respect to the shares of common stock, par value $0.00001 per share, of Pluristem Therapeutics Inc., dated as of April 29, 2020, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) unde |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 24, 2020 (April 24, 2020) PLURISTEM THERAPEUTICS INC. |
|
| April 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 13, 2020 (April 13, 2020) PLURISTEM THERAPEUTICS INC. |
|
| April 7, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 7, 2020 (April 7, 2020) PLURISTEM THERAPEUTICS INC. |
|
| April 7, 2020 |
Exhibit 99.1 Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure · All treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS) · 100% survival rate for all seven patients · 6 patients completed 1 week follow up; the seventh patient was treated o |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2020 (March 30, 2020) PLURISTEM THERAPEUTICS INC. |
|
| March 26, 2020 |
Exhibit 99.1 Pluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity HAIFA, Israel, March 26, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and |
|
| March 26, 2020 |
8-K 1 ea120036-8kpluristem.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2020 (March 26, 2020) PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-31392 98-0351 |
|
| March 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 12, 2020 (March 12, 2020) PLURISTEM THERAPEUTICS INC. |
|
| March 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 3, 2020 (March 3, 2020) PLURISTEM THERAPEUTICS INC. |
|
| February 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name o |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name |
|
| September 12, 2019 |
Exhibit 10.19 Pluristem Therapeutics Inc. 2019 Equity Compensation Plan RESTRICTED STOCK AGREEMENT This Restricted Stock Agreement and the associated grant award information provided in written form or available in electronic form from the recordkeeper (in either case, “Exhibit A”) for the Pluristem Therapeutics Inc. 2019 Equity Compensation Plan, as amended and in effect from time to time (the “P |
|
| September 12, 2019 |
EX-10.20 8 f10k2019ex10-20pluristem.htm RESTRICTED STOCK AGREEMENT FOR ISRAELIS Exhibit 10.20 Pluristem Therapeutics Inc. 2019 Equity Compensation Plan RESTRICTED STOCK AGREEMENT This Restricted Stock Agreement and the associated grant award information provided in written form or available in electronic form from the recordkeeper (in either case, “Exhibit A”) for the Pluristem Therapeutics Inc. 2 |
|
| September 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THER |
|
| September 12, 2019 |
Form of Stock Option Agreement under the 2019 Equity Compensation Plan. + EX-10.18 6 f10k2019ex10-18pluristem.htm STOCK OPTION AGREEMENT Exhibit 10.18 Pluristem Therapeutics Inc. 2019 Equity Compensation Plan STOCK OPTION AGREEMENT This Stock Option Agreement and the associated grant award information provided in written form or available in electronic form from the recordkeeper (in either case, “Exhibit A”) for the Pluristem Therapeutics Inc. 2019 Equity Compensation P |
|
| September 12, 2019 |
Composite Copy (marked) of the Company’s Articles of Incorporation as amended on July 25, 2019. EX-3.2 3 f10k2019ex3-2pluristem.htm COMPOSITE MARKED ARTICLES OF INCORPORATION Exhibit 3.2 PLURISTEM THERAPEUTICS INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of May 22, 2014July 25, 2019 FIRST The name of this corporation is PLURISTEM THERAPEUTICS INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name a |
|
| September 12, 2019 |
Composite Copy of the Company’s Articles of Incorporation as amended on July 25, 2019. Exhibit 3.1 PLURISTEM THERAPEUTICS INC. AMENDED AND RESTATED ARTICLES OF INCORPORATION As amended as of July 25, 2019 FIRST The name of this corporation is PLURISTEM THERAPEUTICS INC. SECOND Its principal office in the State of Nevada is located at 502 East John Street, Carson City, Nevada, 89706. The name and address of its resident agent is CSC Services of Nevada, Inc., at the above address. THI |
|
| September 12, 2019 |
EX-4.3 4 f10k2019ex4-3pluristem.htm DESCRIPTION OF SECURITIES Exhibit 4.3 DESCRIPTION OF SECURITIES Under the Amended and Restated Articles of Incorporation (the “Articles”) of Pluristem Therapeutics Inc. (the “Company”), the Company is authorized to issue up to thirty million (30,000,000) shares of common stock, par value $0.00001 per share (the “Common Stock”) and one million (1,000,000) shares |
|
| September 12, 2019 |
Summary of Directors’ Ongoing Compensation. + Exhibit 10.8 Summary of Directors Ongoing Compensation As of June 30, 2019 our non-executive officer directors receive cash compensation as follows: ● Annual compensation of $15,000; ● Meeting participation fee of $935 per in-person meeting; and ● For meeting participation by telephone, $435 per meeting. If the compensation is paid in New Israeli Shekels (“NIS”), the exchange rate of the directors |
|
| August 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2019 (August 8, 2019) PLURISTEM THERAPEUTICS INC. |
|
| July 25, 2019 |
Exhibit 3.1 Filed in the Office of Business Number C12337-2001 /s/ Barbara K. Cegavske Filing Number Secretary 20190045978 State Of Nevada Filed On 7/23/2019 1:39:00 PM Number of Pages 1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Change Pursuant to NRS 78.209 USE BLACK INK ONLY - DO NOT HIGHLIGH |
|
| July 25, 2019 |
8-K 1 f8k072319pluristemtherape.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 25, 2019 (July 23, 2019) PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-31392 98-0 |
|
| July 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 2, 2019 (June 30, 2019) PLURISTEM THERAPEUTICS INC. |
|
| July 2, 2019 |
Pluristem Therapeutics’ CEO Issues Shareholder Letter Exhibit 99.1 Pluristem Therapeutics’ CEO Issues Shareholder Letter HAIFA, Israel, July 2, 2019 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Yanay. Dear Fellow Shareholders, Following our recently announced CEO t |
|
| June 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 24, 2019 (June 23, 2019) PLURISTEM THERAPEUTICS INC. |
